NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%,…
NEW YORK (Reuters Health) – Results of a randomized study provide no evidence of benefit from high-concentration oxygen therapy relative to titrated oxygen therapy in patients with initially…
NEW YORK (Reuters Health) – In a small randomized study of patients with infected necrotizing pancreatitis, minimally invasive endoscopic transgastric necrosectomy was associated with a lower risk of…
NEW YORK (Reuters Health) – When patients with advanced gastric cancer have not benefitted from one or two chemotherapy regimens for metastatic disease, salvage chemotherapy improves their overall…
NEW YORK (Reuters Health) – Results of a study conducted in Singapore indicate that vasopressin administered to patients in prolonged cardiac arrest does not improve survival to hospital…
NEW YORK (Reuters Health) – In high-risk hypertensive patients with or without prior coronary artery disease, adding the angiotensin receptor II blocker valsartan to conventional non-ARB treatment reduces…
NEW YORK (Reuters Health) – Two independent studies have shown that reduced-activity variants of the cytochrome P450 2D6 (CYP2D6) enzyme are not associated with poorer disease control in…
NEW YORK (Reuters Health) – The lipid-modifying effects of rosuvastatin (Crestor: AstraZeneca) are stronger than atorvastatin (Lipitor; Pfizer) in patients with an acute coronary syndrome (ACS), according to…
NEW YORK (Reuters Health) – The reduced risk of developing invasive breast cancer with adjuvant tamoxifen therapy after lumpectomy and radiation for ductal carcinoma in situ (DCIS) is…
NEW YORK (Reuters Health) – When antiepileptic drug therapy fails to control disabling temporal lobe epilepsy adequately, patients have a much better chance of becoming seizure free with…
